Nicholas Cross

List of Publications by Year in Descending Order

280 papers	26,858 citations	78 h-index	157 g-index
286 ext. papers	29,741 ext. citations	8.2 avg, IF	6.31 L-index

#	Paper	IF	Citations
280	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.. *Journal of Clinical Oncology*, **2022**, JCO2101849	2.2	1
279	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. *British Journal of Haematology*, **2021**, 192, 62-74	4.5	5
278	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. *Leukemia*, **2021**, 35, 3040-3043	10.7	10
277	Adverse Prognostic Impact of the D816V Transcriptional Activity in Advanced Systemic Mastocytosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
276	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. *Leukemia*, **2021**, 35, 2445-2459	10.7	3
275	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. *American Journal of Human Genetics*, **2021**, 108, 284-294	11	6
274	Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. *Leukemia*, **2021**,	10.7	3
273	The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. *British Journal of Haematology*, **2021**, 195, 338-351	4.5	0
272	Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations. *Acta Haematologica*, **2021**, 1-6	2.7	0
271	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. *Leukemia*, **2020**, 34, 2113-2124	10.7	14
270	Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. *Leukemia*, **2020**, 34, 2660-2672	10.7	30
269	Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. *Leukemia*, **2020**, 34, 2279-2284	10.7	6
268	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. *British Journal of Haematology*, **2020**, 191, 171-193	4.5	14
267	Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. *Leukemia*, **2020**, 34, 3206-3214	10.7	1
266	A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. *Acta Haematologica*, **2019**, 142, 105-112	2.7	2
265	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. *Leukemia*, **2019**, 33, 1195-1205	10.7	21
264	Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. *Leukemia*, **2019**, 33, 415-425	10.7	39

263	PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. *Leukemia*, **2019**, 33, 1184-1194	10.7	5
262	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. *Leukemia*, **2019**, 33, 1124-1134	10.7	17
261	Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia. *Acta Haematologica*, **2018**, 139, 71-73	2.7	3
260	Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. *British Journal of Haematology*, **2018**, 182, 777-788	4.5	7
259	Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels. *Acta Haematologica*, **2018**, 139, 217-219	2.7	1
258	Guideline for the investigation and management of eosinophilia. *British Journal of Haematology*, **2017**, 176, 553-572	4.5	73
257	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 1225-1233	4.9	5
256	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. *Haematologica*, **2017**, 102, 1035-1043	6.6	57
255	Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers. *Blood*, **2017**, 130, 137-145	2.2	64
254	The effect of initial molecular profile on response to recombinant interferon-[(rIFN)]treatment in early myelofibrosis. *Cancer*, **2017**, 123, 2680-2687	6.4	31
253	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 1585-1596	4.9	14
252	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia. *Haematologica*, **2017**, 102, e238-e240	6.6	31
251	Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme. *British Journal of Haematology*, **2017**, 177, 414-422	4.5	11
250	Genomics of Myeloproliferative Neoplasms. *Journal of Clinical Oncology*, **2017**, 35, 947-954	2.2	43
249	A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5). *Acta Haematologica*, **2017**, 138, 198-200	2.7	3
248	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. *Journal of Clinical Investigation*, **2017**, 127, 2206-2221	15.9	45
247	Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. *Leukemia*, **2016**, 30, 136-43	10.7	137
246	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. *Leukemia*, **2016**, 30, 57-64	10.7	78

245	Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. *Leukemia*, **2016**, 30, 2342-2350	10.7	53
244	Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation. *Annals of Hematology*, **2016**, 95, 557-62	3	22
243	Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting. *Scientific Reports*, **2016**, 6, 18741	4.9	5
242	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. *Leukemia*, **2016**, 30, 1844-52	10.7	40
241	Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene. *Nucleic Acid Therapeutics*, **2016**, 26, 392-400	4.8	6
240	Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. *Leukemia*, **2016**, 30, 2258-2260	10.7	10
239	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. *European Journal of Clinical Investigation*, **2016**, 46, 392-7	4.6	13
238	Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. *Leukemia*, **2015**, 29, 1115-22	10.7	102
237	Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. *Haematologica*, **2015**, 100, e237-9	6.6	17
236	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia*, **2015**, 29, 1223-32	10.7	164
235	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. *Haematologica*, **2015**, 100, 1117-30	6.6	79
234	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. *Leukemia*, **2015**, 29, 2069-74	10.7	11
233	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nature Communications*, **2015**, 6, 6691	17.4	120
232	Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. *Leukemia Research*, **2015**, 39, 82-7	2.7	47
231	A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. *Leukemia*, **2015**, 29, 369-76	10.7	57
230	Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. *International Journal of Hematology*, **2015**, 101, 229-42	2.3	49
229	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood*, **2015**, 125, 1857-65	2.2	118
228	Neutrophilic leukemoid reaction in multiple myeloma. *American Journal of Hematology*, **2015**, 90, 1090	7.1	3

227	KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. *American Journal of Hematology*, **2015**, 90, 774-7	7.1	38
226	Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. *Genes Chromosomes and Cancer*, **2015**, 54, 762-70	5	22
225	Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3′ splice-site organization and activity of U2AF-related proteins. *Nucleic Acids Research*, **2015**, 43, 3747-63	20.1	25
224	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. *Annals of Hematology*, **2015**, 94, 233-8	3	54
223	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia*, **2015**, 29, 999-1003	10.7	229
222	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. *Nature Communications*, **2015**, 6, 5901	17.4	149
221	Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. *Leukemia*, **2015**, 29, 1600-2	10.7	15
220	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. *Blood*, **2014**, 123, 3574-7	2.2	91
219	Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. *Nature Genetics*, **2014**, 46, 624-8	36.3	213
218	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia*, **2014**, 28, 1804-10	10.7	213
217	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. *Annals of Hematology*, **2014**, 93, 81-8	3	113
216	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. *British Journal of Haematology*, **2014**, 167, 421-3	4.5	30
215	The future of JAK inhibition in myelofibrosis and beyond. *Blood Reviews*, **2014**, 28, 189-96	11.1	24
214	Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. *Leukemia*, **2014**, 28, 2106-9	10.7	16
213	A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. *Leukemia*, **2014**, 28, 1570-2	10.7	25
212	Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. *Genes Chromosomes and Cancer*, **2014**, 53, 411-21	5	20
211	Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations. *PLoS ONE*, **2014**, 9, e86940	3.7	17
210	Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. *British Journal of Haematology*, **2013**, 163, 235-9	4.5	33

209	Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. *Leukemia*, **2013**, 27, 2105-7	10.7	16
208	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. *Leukemia*, **2013**, 27, 2032-9	10.7	78
207	Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *New England Journal of Medicine*, **2013**, 369, 2391-2405	59.2	1262
206	JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. *Leukemia*, **2013**, 27, 1763-7	10.7	20
205	Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*, **2013**, 122, 3616-27; quiz 3699	2.2	1169
204	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. *Blood*, **2013**, 121, 468-75	2.2	167
203	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. *Nature Genetics*, **2013**, 45, 18-24	36.3	272
202	Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. *Leukemia and Lymphoma*, **2013**, 54, 1527-31	1.9	9
201	Prognostic score including gene mutations in chronic myelomonocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 2428-36	2.2	373
200	Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood*, **2013**, 122, 2460-6	2.2	183
199	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. *British Journal of Haematology*, **2013**, 160, 25-34	4.5	68
198	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. *Clinical Chemistry*, **2013**, 59, 938-48	5.5	38
197	Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?. *Leukemia*, **2013**, 27, 1930-2	10.7	4
196	Mutations and prognosis in primary myelofibrosis. *Leukemia*, **2013**, 27, 1861-9	10.7	520
195	Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. *Haematologica*, **2013**, 98, 103-6	6.6	60
194	Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. *Leukemia*, **2013**, 27, 2254-6	10.7	46
193	Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. *Haematologica*, **2013**, 98, 404-8	6.6	26
192	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. *Haematologica*, **2013**, 98, 576-83	6.6	9

191	Impact of isolated germline JAK2V617I mutation on human hematopoiesis. *Blood*, **2013**, 121, 4156-65	2.2	40
190	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. *Haematologica*, **2013**, 98, 1414-20	6.6	37
189	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. *Blood*, **2012**, 119, 1208-13	2.2	144
188	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. *Annals of Hematology*, **2012**, 91, 1713-20	3	26
187	TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. *PLoS ONE*, **2012**, 7, e31605	3.7	66
186	Acquired uniparental disomy in myeloproliferative neoplasms. *Hematology/Oncology Clinics of North America*, **2012**, 26, 981-91	3.1	12
185	Standardized definitions of molecular response in chronic myeloid leukemia. *Leukemia*, **2012**, 26, 2172-5	10.7	293
184	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. *Blood*, **2012**, 119, 3211-8	2.2	188
183	Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. *Pediatric Blood and Cancer*, **2012**, 59, 194-6	3	19
182	Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. *Leukemia*, **2012**, 26, 162-4	10.7	49
181	Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib. *Journal of Clinical Oncology*, **2012**, 30, e109-11	2.2	4
180	Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. *Haematologica*, **2012**, 97, 538-42	6.6	26
179	Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. *Leukemia*, **2011**, 25, 877-9	10.7	120
178	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood*, **2011**, 118, 1208-15	2.2	395
177	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. *Blood*, **2011**, 117, 2935-43	2.2	67
176	Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. *Blood*, **2011**, 118, 2239-42	2.2	61
175	EZH2 mutational status predicts poor survival in myelofibrosis. *Blood*, **2011**, 118, 5227-34	2.2	204
174	The European LeukemiaNet: achievements and perspectives. *Haematologica*, **2011**, 96, 156-62	6.6	12

173	Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. *British Journal of Haematology*, **2011**, 153, 43-6	4.5	30
172	Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. *British Journal of Haematology*, **2011**, 153, 179-90	4.5	76
171	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. *Leukemia*, **2011**, 25, 178-81	10.7	20
170	The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia. *Leukemia*, **2011**, 25, 1049-50	10.7	1
169	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. *Annals of Hematology*, **2011**, 90, 365-6	3	6
168	JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. *Leukemia Research*, **2011**, 35, 177-82	2.7	48
167	Aberrations of EZH2 in cancer. *Clinical Cancer Research*, **2011**, 17, 2613-8	12.9	422
166	Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. *Cell Cycle*, **2011**, 10, 250-60	4.7	56
165	Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. *Leukemia*, **2010**, 24, 1742-50	10.7	33
164	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. *Nature Genetics*, **2010**, 42, 722-6	36.3	897
163	Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning. *Clinical Chemistry*, **2010**, 56, 593-602	5.5	11
162	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. *Blood*, **2010**, 116, e111-7	2.2	120
161	No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166. *Haematologica*, **2010**, 95, 1226-1227	6.6	3
160	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. *Blood*, **2010**, 115, 4517-23	2.2	80
159	TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. *Haematologica*, **2010**, 95, 20-6	6.6	45
158	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. *Haematologica*, **2010**, 95, 1473-80	6.6	57
157	A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon *Haematologica*, **2010**, 95, 148-52	6.6	23
156	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. *Haematologica*, **2010**, 95, 738-44	6.6	60

155	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. *Haematologica*, **2010**, 95, 1221-5	6.6	67
154	In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. *Blood*, **2010**, 116, 1329-35	2.2	71
153	Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia. *Genes Chromosomes and Cancer*, **2010**, 49, 471-9	5	20
152	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. *Haematologica*, **2009**, 94, 1024-8	6.6	41
151	Frequent upregulation of MYC in plasma cell leukemia. *Genes Chromosomes and Cancer*, **2009**, 48, 624-36	5	56
150	No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. *British Journal of Haematology*, **2009**, 144, 802-3	4.5	11
149	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. *British Journal of Haematology*, **2009**, 144, 904-8	4.5	72
148	Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene. *British Journal of Haematology*, **2009**, 146, 225-7	4.5	10
147	Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. *Leukemia*, **2009**, 23, 358-64	10.7	11
146	Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. *Leukemia*, **2009**, 23, 332-9	10.7	29
145	The molecular anatomy of the FIP1L1-PDGFRA fusion gene. *Leukemia*, **2009**, 23, 271-8	10.7	16
144	Harmonization of molecular monitoring of CML therapy in Europe. *Leukemia*, **2009**, 23, 1957-63	10.7	170
143	Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. *Bone Marrow Transplantation*, **2009**, 44, 197-9	4.4	3
142	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. *Nature Genetics*, **2009**, 41, 446-9	36.3	320
141	Standardisation of molecular monitoring for chronic myeloid leukaemia. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 355-65	4.2	70
140	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. *Haematologica*, **2009**, 94, 1708-13	6.6	60
139	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. *Blood*, **2009**, 113, 6182-92	2.2	321
138	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. *Leukemia*, **2008**, 22, 1320-34	10.7	23

137	JAK2 Mutations are present in all cases of polycythemia vera. *Leukemia*, **2008**, 22, 1289	10.7	47
136	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. *British Journal of Haematology*, **2008**, 143, 707-15	4.5	104
135	Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. *Acta Haematologica*, **2008**, 119, 199-206	2.7	52
134	Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. *Haematologica*, **2008**, 93, 1560-4	6.6	46
133	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. *Blood*, **2008**, 112, 3330-8	2.2	306
132	Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. *International Journal of Hematology*, **2008**, 88, 197-201	2.3	9
131	The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. *Genes Chromosomes and Cancer*, **2008**, 47, 379-85	5	46
130	International standardisation of quantitative real-time RT-PCR for BCR-ABL. *Leukemia Research*, **2008**, 32, 505-6	2.7	27
129	Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes. *Clinical Chemistry*, **2007**, 53, 1960-2	5.5	80
128	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. *Haematologica*, **2007**, 92, 163-9	6.6	71
127	Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. *Acta Haematologica*, **2007**, 118, 209-14	2.7	16
126	FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. *Leukemia*, **2007**, 21, 397-402	10.7	20
125	Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. *Leukemia*, **2007**, 21, 1183-8	10.7	140
124	A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. *Leukemia*, **2007**, 21, 1839-41	10.7	27
123	The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. *Leukemia*, **2007**, 21, 2428-32	10.7	23
122	Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. *British Journal of Haematology*, **2007**, 138, 77-81	4.5	66
121	A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. *Experimental Hematology*, **2007**, 35, 1723-7	3.1	36
120	Simultaneous MLPA-based multiplex point mutation and deletion analysis of the dystrophin gene. *Molecular Biotechnology*, **2007**, 35, 135-40	3	21

119	Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. *Pathobiology*, **2007**, 74, 81-8	3.6	24
118	Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. *Blood*, **2007**, 109, 61-4	2.2	136
117	Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. *Blood*, **2007**, 110, 3729-34	2.2	82
116	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. *Blood*, **2007**, 109, 4635-40	2.2	167
115	Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. *Blood*, **2007**, 110, 1283-90	2.2	62
114	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. *Blood*, **2007**, 110, 3291-300	2.2	121
113	Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. *Current Drug Targets*, **2007**, 8, 205-16	3	25
112	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. *Journal of Molecular Diagnostics*, **2007**, 9, 272-6	5.1	54
111	Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. *Haematologica*, **2007**, 92, 1153-8	6.6	12
110	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. *Genes Chromosomes and Cancer*, **2006**, 45, 950-6	5	58
109	Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. *European Respiratory Journal*, **2006**, 27, 230-2	13.6	31
108	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*, **2006**, 108, 28-37	2.2	977
107	Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 535-69	4.2	48
106	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. *Clinical Science*, **2006**, 111, 233-49	6.5	7
105	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. *Blood*, **2006**, 107, 4171-6	2.2	108
104	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. *Blood*, **2006**, 107, 3339-41	2.2	107
103	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). *Blood*, **2006**, 108, 1497-503	2.2	287
102	JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. *Leukemia*, **2006**, 20, 534-5	10.7	40

101	Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. *Leukemia*, **2006**, 20, 827-32	10.7	101
100	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. *Leukemia*, **2006**, 20, 1610-7	10.7	124
99	JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. *Leukemia*, **2006**, 20, 2067	10.7	38
98	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. *Leukemia*, **2006**, 20, 1925-30	10.7	164
97	A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. *Leukemia Research*, **2006**, 30, 373-8	2.7	111
96	Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. *Genetic Testing and Molecular Biomarkers*, **2005**, 9, 190-9		84
95	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. *Blood*, **2005**, 106, 2162-8	2.2	706
94	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *New England Journal of Medicine*, **2005**, 353, 33-45	59.2	714
93	Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. *Journal of Pediatric Hematology/Oncology*, **2005**, 27, 663-5	1.2	31
92	NUP98-LEDGF fusion and t(9;11) in transformed chronic myeloid leukemia. *Leukemia Research*, **2005**, 29, 1469-72	2.7	26
91	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **2005**, 130, 229-32	4.5	37
90	Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. *Leukemia*, **2005**, 19, 245-52	10.7	59
89	Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. *Leukemia*, **2005**, 19, 1096-9	10.7	16
88	The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. *Leukemia*, **2005**, 19, 1005-9	10.7	77
87	Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. *Leukemia*, **2005**, 19, 1634-42	10.7	64
86	Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. *International Journal of Cancer*, **2005**, 114, 94-100	7.5	55
85	DNA topoisomerase II in therapy-related acute promyelocytic leukemia. *New England Journal of Medicine*, **2005**, 352, 1529-38	59.2	229
84	The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. *Cancer Research*, **2005**, 65, 2662-7	10.1	231

83	p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. *Cancer Research*, **2004**, 64, 7216-9	10.1	66
82	NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. *Cancer Research*, **2004**, 64, 2673-6	10.1	61
81	Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. *Journal of Biological Chemistry*, **2004**, 279, 6666-73	5.4	39
80	Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. *British Journal of Haematology*, **2004**, 126, 508-11	4.5	10
79	Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. *Leukemia*, **2004**, 18, 962-6	10.7	128
78	Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. *British Journal of Cancer*, **2004**, 91, 1155-9	8.7	155
77	Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. *Cancer Cell*, **2004**, 5, 287-98	24.3	131
76	Oncogenic derivatives of platelet-derived growth factor receptors. *Cellular and Molecular Life Sciences*, **2004**, 61, 2912-23	10.3	118
75	Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. *Genes Chromosomes and Cancer*, **2004**, 40, 78-83	5	78
74	Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. *Current Genomics*, **2004**, 5, 431-438	2.6	7
73	Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. *The Hematology Journal*, **2004**, 5, 534-7		39
72	A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *New England Journal of Medicine*, **2003**, 348, 1201-14	59.2	1426
71	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. *Blood*, **2003**, 101, 3391-7	2.2	187
70	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood*, **2003**, 102, 3093-6	2.2	327
69	MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. *Cancer Cell*, **2003**, 3, 259-71	24.3	170
68	Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. *Genes Chromosomes and Cancer*, **2003**, 36, 175-88	5	52
67	Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. *British Journal of Haematology*, **2003**, 120, 251-6	4.5	72
66	P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. *Leukemia*, **2003**, 17, 2097-100	10.7	40

65	Imatinib for systemic mast-cell disease. *Lancet, The*, **2003**, 362, 535-6	40	207
64	Tyrosine kinase fusion genes in chronic myeloproliferative diseases. *Leukemia*, **2002**, 16, 1207-12	10.7	111
63	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. *Leukemia*, **2002**, 16, 2190-6	10.7	769
62	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. *Human Molecular Genetics*, **2002**, 11, 1391-7	5.6	109
61	Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. *New England Journal of Medicine*, **2002**, 347, 481-7	59.2	546
60	The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. *Acta Haematologica*, **2002**, 107, 101-7	2.7	189
59	Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. *Acta Haematologica*, **2002**, 107, 108-12	2.7	23
58	Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. *Acta Haematologica*, **2002**, 107, 113-22	2.7	140
57	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. *Blood*, **2001**, 98, 2879-80	2.2	33
56	Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood*, **2001**, 97, 1560-5	2.2	135
55	The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. *Blood*, **2001**, 97, 2604-10	2.2	42
54	The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. *Blood*, **2001**, 98, 3778-83	2.2	171
53	A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. *Blood*, **2001**, 98, 1264-7	2.2	214
52	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. *British Journal of Haematology*, **2001**, 115, 569-74	4.5	55
51	Identification of four new translocations involving FGFR1 in myeloid disorders. *Genes Chromosomes and Cancer*, **2001**, 32, 155-63	5	73
50	Mutations of the transcription factor AML1/CBFA2 are uncommon in blastic transformation of chronic myeloid leukaemia. *Leukemia*, **2001**, 15, 476-7	10.7	8
49	Myeloproliferative disorders. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 531-51	4.2	37
48	Cytogenetics of chronic myeloid leukaemia. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 553-71	4.2	29

47	Detection and quantification of residual disease in chronic myelogenous leukemia. *Leukemia*, **2000**, 14, 998-1005	10.7	87
46	Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11-->q12. *Cytogenetic and Genome Research*, **2000**, 89, 24-8	1.9	5
45	Assignment of ZNF262 to human chromosome band 1p34-->p32 by in situ hybridization. *Cytogenetic and Genome Research*, **1999**, 85, 306-7	1.9	7
44	A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders. *British Journal of Haematology*, **1999**, 105, 771-4	4.5	5
43	Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. *British Journal of Haematology*, **1999**, 106, 634-43	4.5	45
42	Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. *British Journal of Haematology*, **1999**, 105, 434-436	4.5	25
41	Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. *Leukemia*, **1999**, 13, 1825-32	10.7	232
40	Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). *Cancer Genetics and Cytogenetics*, **1999**, 113, 70-2		48
39	The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. *Genomics*, **1999**, 55, 118-21	4.3	16
38	Cloning and characterization of RNF6, a novel RING finger gene mapping to 13q12. *Genomics*, **1999**, 58, 94-7	4.3	17
37	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. *Bone Marrow Transplantation*, **1998**, 21, 1055-61	4.4	61
36	Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. *British Journal of Cancer*, **1998**, 78, 601-5	8.7	10
35	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. *British Journal of Haematology*, **1998**, 102, 1271-8	4.5	14
34	A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. *British Journal of Haematology*, **1998**, 103, 791-4	4.5	19
33	Assignment of the steroid receptor coactivator-1 (SRC-1) gene to human chromosome band 2p23. *Genomics*, **1998**, 52, 242-4	4.3	9
32	The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. *Leukemia*, **1997**, 11, 233-8	10.7	27
31	An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia. *Leukemia*, **1997**, 11, 614-6	10.7	2
30	Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia. *Leukemia*, **1997**, 11, 1005-8	10.7	24

29	Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group. *British Journal of Haematology*, **1997**, 97, 86-93	4.5	31
28	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. *British Journal of Haematology*, **1997**, 99, 945-50	4.5	63
27	Rarity of microsatellite alterations in acute myeloid leukaemia. *British Journal of Cancer*, **1996**, 74, 255-7	8.7	34
26	Mutational analysis of the p15 and p16 genes in acute leukaemias. *British Journal of Haematology*, **1996**, 92, 681-3	4.5	22
25	Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. *British Journal of Haematology*, **1996**, 95, 95-101	4.5	35
24	TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. *British Journal of Haematology*, **1996**, 95, 673-7	4.5	79
23	Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. *British Journal of Haematology*, **1995**, 90, 138-46	4.5	59
22	Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. *British Journal of Haematology*, **1995**, 91, 126-31	4.5	70
21	Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 Mbp region of chromosome 13. *Genes Chromosomes and Cancer*, **1995**, 12, 283-7	5	23
20	Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. *Genes Chromosomes and Cancer*, **1995**, 13, 110-4	5	17
19	Null alleles of the aldolase B gene in patients with hereditary fructose intolerance. *Journal of Medical Genetics*, **1994**, 31, 499-503	5.8	14
18	A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. *British Journal of Haematology*, **1994**, 86, 683-5	4.5	50
17	An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case. *British Journal of Haematology*, **1994**, 86, 879-80	4.5	43
16	Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR). *British Journal of Haematology*, **1994**, 87, 218	4.5	14
15	Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). *British Journal of Haematology*, **1994**, 88, 400-2	4.5	12
14	Isolation and characterization of the genes encoding mouse and human type-5 acid phosphatase. *Gene*, **1993**, 130, 201-7	3.8	44
13	BCR-ABL antisense purging in chronic myeloid leukaemia. *Lancet, The*, **1993**, 342, 614	40	29
12	Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. *Leukemia and Lymphoma*, **1993**, 11 Suppl 1, 39-43	1.9	51

11	Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. *British Journal of Haematology*, **1993**, 84, 67-74	4.5	134
10	Aldolase B mutations in Italian families affected by hereditary fructose intolerance. *Journal of Medical Genetics*, **1991**, 28, 241-3	5.8	19
9	Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage. *FEBS Journal*, **1990**, 189, 287-93		76
8	Hereditary fructose intolerance. *International Journal of Biochemistry & Cell Biology*, **1990**, 22, 685-9		11
7	A new aldolase B variant, N334K, is a common cause of hereditary fructose intolerance in Yugoslavia. *Nucleic Acids Research*, **1990**, 18, 1925	20.1	24
6	Molecular analysis of aldolase B genes in hereditary fructose intolerance. *Lancet, The*, **1990**, 335, 306-9	40	103
5	Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. *Cell*, **1988**, 53, 881-5	56.2	82
4	A potent inhibitor of Taq polymerase copurifies with human genomic DNA. *Nucleic Acids Research*, **1988**, 16, 10355	20.1	118
3	Polymerase chain reaction automated at low cost. *Nucleic Acids Research*, **1988**, 16, 5687-8	20.1	20
2	Tsetse fly rDNA: an analysis of structure and sequence. *Nucleic Acids Research*, **1987**, 15, 15-30	20.1	37
1	A novel arrangement of sequence elements surrounding the rDNA promoter and its spacer duplications in tsetse species. *Journal of Molecular Biology*, **1987**, 195, 63-74	6.5	16